|
|
 |
|
Viewing report
|
|
|
|
Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth
GBI Research, Sep 2011, Pages: 150
“Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth” provides in-depth analysis of the drivers and barriers that affect the global gastrointestinal disorder therapeutics market. The report analyzes the markets for gastrointestinal disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2017 for the key geographic regions as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
It is compiled using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
This report finds that the gastrointestinal disorder therapeutics market will decline during the period 2010-2017. This decline will primarily be driven by the negative growth of the gastroesophageal reflux disease (GERD) therapeutics market, which is attributed to the loss of drug patents and the entry of generics. However, other key gastrointestinal markets, such as Crohn’s disease and irritable bowel syndrome therapeutics, will continue to grow due to a strong late stage pipeline that will address unmet needs. The global gastrointestinal disorder therapeutics market is a highly fragmented market, where the big players face stiff competition. The forthcoming patent expiries of major drugs have increased competition, driving the consolidation further. This increasing pressure has also driven companies to enter into licensing agreements. This allows companies to expand their product portfolios and improve their competitive positions in the market.
Scope
The scope of this report includes -
- Annualized market data for the gastrointestinal disorder therapeutics market from 2001 to 2010, and forecast to 2017.
- Analysis of the leading therapeutic segments. These include Crohn’s disease, ulcerative colitis, irritable bowel syndrome and gastroesophageal reflux disease.
- Analysis of the gastrointestinal disorder therapeutic markets in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the gastrointestinal disorder therapeutics market, including market size, revenue analysis by top seven geographies, generic share, annual cost of therapy, treatment flow algorithm and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of the pipeline molecules in various phases of drug development.
- Competitive benchmarking of the leading companies. The key companies studied in this report are AstraZeneca, Pfizer Inc, Abbott Laboratories, Johnson & Johnson, Salix Pharmaceuticals, Takeda Pharmaceutical Company Ltd. and Shire Plc.
- Key M&A activities and licensing agreements that have taken place between 2008 and 2011 in the global gastrointestinal disorder therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of the leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
|
|
|
|
